John W. Walsh Alpha-1 Home Infusion Act of 2025
Current understanding
Introduced legislation that would amend Medicare to cover at-home augmentation therapy furnished by qualified home infusion suppliers for beneficiaries with emphysema due to severe hereditary alpha-1 antitrypsin (AAT) deficiency. If enacted, it would shift a currently outpatient/facility-based infusion regimen into the home setting for Medicare beneficiaries, expanding site-of-care options for an established rare-disease treatment. Status: introduced.
Evidence log
- 2025-12-10 — Joe Fiandra Access to Home Infusion Act of 2025: cross-connection with joe-fiandra-access-to-home-infusion-act: Both bills would expand Medicare coverage of home infusion therapies, with the Fiandra bill setting a general frequency/supervision threshold for external-pump drugs and the Walsh bill creating a disease-specific pathway for Alpha-1 AAT augmentation therapy. (novelty: 3)